||Proglumide is a cholecystokinin antagonist, which blocks both the CCKA and CCKB subtypes. Proglumide is a drug that exerts an inhibitory effect on gastric secretion and reduces gas
||Loxiglumide is a cholecystokinin (CCK-1) receptor antagonist.
||PHA-767491 is an effective ATP-competitive dual Cdc7/CDK9 inhibitor (IC50: 10/34 nM). It has ~20-fold selectivity against GSK3-β and CDK1/2, 50-fold selectivity against CDK5 and M
||Nastorazepide (Z-360) is a selective, orally available antagonist of gastrin/cholecystokinin 2 (CCK-2) receptor with potential antineoplastic activity.
||XL-413 is an orally bioavailable cell division cycle 7 homolog (CDC7) kinase inhibitor with potential antineoplastic activity. XL-413 binds to and inhibits the activity of CDC7, wh
||XL-413 is an orally bioavailable cell division cycle 7 homolog (CDC7) kinase inhibitor with potential antineoplastic activity. CDC7 kinase inhibitor BMS-863233 binds to and inhibit
||PHA-767491 is a potent ATP-competitive dual Cdc7/CDK9 inhibitor with IC50 of 10 nM and 34 nM, respectively.
||Lintitript is a highly potent, selective, orally active, competitive, and non-peptide cholecystokinin (CCK1) receptor antagonist (EC50: 6 nM and a Ki: 0.2 nM). Lintitript enhances
||Lorglumide sodium salt
||Lorglumide sodium salt is a potent cholecystokinin (CCK) receptor antagonist.